X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pibrentasvir (103) 103
glecaprevir (97) 97
index medicus (76) 76
hepatitis c (58) 58
hepatitis c virus (55) 55
hcv (51) 51
sofosbuvir (50) 50
gastroenterology & hepatology (37) 37
hepatitis (37) 37
efficacy (31) 31
patients (30) 30
glecaprevir/pibrentasvir (28) 28
humans (28) 28
safety (28) 28
velpatasvir (28) 28
genotypes (27) 27
cirrhosis (25) 25
ribavirin (25) 25
pharmacology & pharmacy (24) 24
hepatitis c, chronic - drug therapy (23) 23
antiviral agents (22) 22
interferon (22) 22
genotype (20) 20
hcv genotype 1 (20) 20
infection (20) 20
viruses (19) 19
infections (18) 18
therapy (18) 18
genotype 1 (17) 17
direct-acting antivirals (16) 16
health aspects (16) 16
sustained virologic response (16) 16
antiviral agents - therapeutic use (15) 15
chronic infection (15) 15
infectious diseases (15) 15
microbiology (15) 15
drug therapy, combination (14) 14
female (14) 14
hepacivirus - genetics (14) 14
medicine & public health (14) 14
open-label (14) 14
daclatasvir (13) 13
genotype & phenotype (13) 13
hepatology (13) 13
male (13) 13
benzimidazoles - therapeutic use (12) 12
chronic hepatitis c (12) 12
clinical trials (12) 12
ledipasvir (12) 12
liver (12) 12
middle aged (12) 12
prevalence (12) 12
protease inhibitors (12) 12
quinoxalines - therapeutic use (12) 12
resistance (12) 12
sulfonamides - therapeutic use (12) 12
virus diseases (12) 12
virus genotype 1 (12) 12
6 infection (11) 11
adult (11) 11
antiviral agents - administration & dosage (11) 11
combination (11) 11
compensated cirrhosis (11) 11
gastroenterology (11) 11
medical research (11) 11
aged (10) 10
antiretroviral drugs (10) 10
care and treatment (10) 10
fibrosis (10) 10
hemodialysis (10) 10
liver diseases (10) 10
retreatment (10) 10
sustained virological response (10) 10
benzimidazoles - administration & dosage (9) 9
benzimidazoles - adverse effects (9) 9
colorectal surgery (9) 9
direct-acting antiviral (9) 9
hepacivirus - drug effects (9) 9
medicine, general & internal (9) 9
pharmacokinetics (9) 9
pruritus (9) 9
quinoxalines - administration & dosage (9) 9
sulfonamides - administration & dosage (9) 9
treatment outcome (9) 9
treatment-naive (9) 9
virus-infection (9) 9
abdominal surgery (8) 8
drug combinations (8) 8
liver cirrhosis (8) 8
medicine, experimental (8) 8
proteinase inhibitors (8) 8
quinoxalines - adverse effects (8) 8
sulfonamides - adverse effects (8) 8
surgical oncology (8) 8
voxilaprevir (8) 8
asunaprevir (7) 7
drug therapy (7) 7
epidemiology (7) 7
genetic aspects (7) 7
hepatitis c, chronic - complications (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Internal Medicine, ISSN 0918-2918, 2019
Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs).... 
pibrentasvir | hemodialysis | HCV | retreatment | glecaprevir
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 03/2018, Volume 16, Issue 3, pp. 417 - 426
Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment... 
Direct-acting Antiviral | Short-duration | DAA | Pangenotypic | GLECAPREVIR | VELPATASVIR | PIBRENTASVIR | NS5A | SOFOSBUVIR | ADULTS | HCV | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 11/2019, Volume 69, Issue 10, pp. 1657 - 1664
Background. Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This... 
INFECTIOUS DISEASES | chronic kidney disease | GLECAPREVIR | EFFICACY | adverse event | RISK | MICROBIOLOGY | IMMUNOLOGY | VIROLOGICAL RESPONSE | RATES | HEPATOCELLULAR-CARCINOMA | PIBRENTASVIR | CIRRHOSIS | compensated cirrhosis | HCV | glecaprevir/pibrentasvir | Index Medicus | Major and Commentaries | pibrentasvir | glecaprevir
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV)... 
hemophilia | HIV | pibrentasvir | HCV | genotype 3 | glecaprevir
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 557 - 565
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A... 
Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Glecaprevir/pibrentasvir | Hepatitis C virus | Surgical Oncology | Direct-acting antivirals | ASIA | PHASE-3 TRIAL | RIBAVIRIN | COMPENSATED CIRRHOSIS | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Anilides - therapeutic use | Age Distribution | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Sulfonamides - blood | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - blood | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Drug Administration Schedule | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Viral Nonstructural Proteins - genetics | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Macrocyclic Compounds - therapeutic use | Liver Cirrhosis - virology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Virus diseases | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | Genetic aspects | Health aspects | Liver cirrhosis | Cirrhosis | Antiviral agents | Ritonavir | Chronic infection | Proteinase inhibitors | Hepatitis C | Patients | Genotypes | Glecaprevir | pibrentasvir | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal of Medical Virology, ISSN 0146-6615, 01/2019, Volume 91, Issue 1, pp. 102 - 106
Journal Article
Journal of Hepatology, ISSN 0168-8278, 05/2019, Volume 70, Issue 5, pp. 1019 - 1023
Curative treatment of patients who previously failed hepatitis C virus (HCV) therapies is critical to achieving HCV elimination. Glecaprevir/pibrentasvir (G/P)... 
Resistance | Retreatment | G/P | HCV | RAS | SOFOSBUVIR | OPEN-LABEL | RIBAVIRIN | HCV INFECTION | GENOTYPE 1 | VELPATASVIR | PIBRENTASVIR | CLINICAL-TRIALS | RESISTANCE-ASSOCIATED SUBSTITUTIONS | GASTROENTEROLOGY & HEPATOLOGY | ANTIVIRAL DRUGS | Hepatitis C
Journal Article
Gastroenterology & Hepatology, ISSN 1554-7914, 5/2019, Volume 15, Issue 5 Suppl 3, pp. 1 - 12
Elimination of hepatitis C virus (HCV) infection as a public health threat is a goal of the World Health Organization. Official treatment guidelines are... 
sofosbuvir | pibrentasvir | Column | velpatasvir | simplified treatment | Hepatitis C | glecaprevir
Journal Article
Journal of Hepatology, ISSN 0168-8278, 11/2018, Volume 69, Issue 5, pp. 1178 - 1187
Journal Article